AM-2233
外观
![]() | |
法律規範狀態 | |
---|---|
法律規範 |
|
识别信息 | |
| |
CAS号 | 444912-75-8 ![]() |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.233.382 |
化学信息 | |
化学式 | C22H23IN2O |
摩尔质量 | 458.34 g·mol−1 |
3D模型(JSmol) | |
| |
|
AM-2233,化学名:1-[(N-甲基-2-哌啶基)甲基]-3-(2-碘苯甲酰基)吲哚,分子式C22H23IN2O,属于亚历山德罗斯·马克里扬尼斯小组合成的苯甲酰基吲哚类AM系列大麻素[1][2],2015年列入《非药用类麻醉药品和精神药品名录》[3]。
参考文献
[编辑]- ^ Deng H, Gifford AN, Zvonok AM, Cui G, Li X, Fan P, et al. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. Journal of Medicinal Chemistry. October 2005, 48 (20): 6386–6392. PMID 16190764. doi:10.1021/jm050135l.
- ^ Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, et al. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chemistry & Biology. November 2008, 15 (11): 1207–1219. PMC 3700404
. PMID 19022181. doi:10.1016/j.chembiol.2008.10.011.
- ^ 关于印发《非药用类麻醉药品和精神药品列管办法》的通知. China Food and Drug Administration. 27 September 2015 [1 October 2015]. (原始内容存档于1 October 2015) (中文).